Recently, the glucocorticoid system has drawn considerable interest in the field of ovarian cancer therapy, with studies involving, for instance, glucocorticoids-induced chemotherapy resistance in ovarian cancer cells[5,6]; GR may be involved in the pathogenesis of ovarian cancer via the regulation of apoptosis and aberrant cell migration[7]. The gene discussed is NR3C1; the disease is ovarian carcinoma.